OncoMatch/Clinical Trials/NCT06778863
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Is NCT06778863 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CLSP-1025 for advanced solid tumor.
Treatment: CLSP-1025 — Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Colorectal Cancer
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Ovarian Cancer
Breast Carcinoma
Head and Neck Squamous Cell Carcinoma
Prostate Cancer
Urothelial Carcinoma
Biomarker criteria
Required: TP53 R175H
Tumors must harbor a TP53 R175H variant mutation confirmed by an accredited laboratory-based test
Required: HLA-A A*02:01 positive
Patients must be HLA-A*02:01 positive by central assay
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: p53 r175h-directed therapy
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- HonorHealth Research Institute · Scottsdale, Arizona
- The University of Arizona Cancer Center · Tucson, Arizona
- USC - Norris Comprehensive Cancer Center · Los Angeles, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
- University of California San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06778863 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior p53 r175h-directed therapy disqualifies patients from enrollment.
Does this trial require TP53?
Yes, TP53 R175H is a required biomarker for enrollment.
Does this trial require HLA-A?
Yes, HLA-A A*02:01 positive is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages